William Scheessele - Humacyte Chief Officer
| HUMA Stock | USD 5.52 1.60 4.49% |
Insider
William Scheessele is Chief Officer of Humacyte
| Age | 53 |
| Phone | 919 313 9633 |
| Web | https://www.humacyte.com |
William Scheessele Latest Insider Activity
Tracking and analyzing the buying and selling activities of William Scheessele against Humacyte stock is an integral part of due diligence when investing in Humacyte. William Scheessele insider activity provides valuable insight into whether Humacyte is net buyers or sellers over its current business cycle. Note, Humacyte insiders must abide by specific rules, including filing SEC forms every time they buy or sell Humacyte'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
William Scheessele over three weeks ago Acquisition by William Scheessele of 276000 shares of Humacyte at 2.8 subject to Rule 16b-3 | ||
William Scheessele over six months ago Acquisition by William Scheessele of 136000 shares of Humacyte subject to Rule 16b-3 |
Humacyte Management Efficiency
The company has return on total asset (ROA) of (0.5323) % which means that it has lost $0.5323 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.5081) %, meaning that it created substantial loss on money invested by shareholders. Humacyte's management efficiency ratios could be used to measure how well Humacyte manages its routine affairs as well as how well it operates its assets and liabilities.Humacyte currently holds 57.51 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Humacyte has a current ratio of 17.11, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Humacyte's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jason Cavalier | Lyra Therapeutics | 51 | |
| John CPA | MediciNova | N/A | |
| Chris MBA | Crinetics Pharmaceuticals | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Marc MD | Kura Oncology | 50 | |
| Annelise Vuidepot | Immunocore Holdings | N/A | |
| Todd IRC | Viridian Therapeutics | N/A | |
| Joe Laws | Seer Inc | N/A | |
| Stephen MD | Kura Oncology | 53 | |
| Jason CPA | MediciNova | 47 | |
| Clayton Robertson | Immunocore Holdings | N/A | |
| Scott Thomas | Seer Inc | 51 | |
| FACC MD | Cytokinetics | 58 | |
| Kenny Ross | Seer Inc | N/A | |
| Peter MBA | Mirum Pharmaceuticals | 47 | |
| Jeff Knight | Crinetics Pharmaceuticals | 54 | |
| MSC MBA | Mirum Pharmaceuticals | 55 | |
| James Spudich | Cytokinetics | 83 | |
| Paul Ross | Mirum Pharmaceuticals | N/A | |
| Thomas MBA | Kalvista Pharmaceuticals | 49 | |
| Kari JD | Cytokinetics | N/A | |
Management Performance
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 |
Humacyte Leadership Team
Elected by the shareholders, the Humacyte's board of directors comprises two types of representatives: Humacyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Humacyte. The board's role is to monitor Humacyte's management team and ensure that shareholders' interests are well served. Humacyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Humacyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juliana Blum, CoFounder Advisor | ||
| Harold Alterson, Senior Quality | ||
| Sabrina Osborne, Executive People | ||
| Dale Sander, Chief CFO | ||
| William Scheessele, Chief Officer | ||
| Yang MD, Chief Officer | ||
| Shamik MD, Chief Officer | ||
| SPHR GPHR, Chief Officer | ||
| Heather Prichard, Chief Officer |
Humacyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Humacyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 427.74 M | ||||
| Shares Outstanding | 128.67 M | ||||
| Shares Owned By Insiders | 26.87 % | ||||
| Shares Owned By Institutions | 35.01 % | ||||
| Number Of Shares Shorted | 24.08 M | ||||
| Price To Earning | 18.04 X | ||||
| Price To Book | 30.28 X | ||||
| Price To Sales | 153.91 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.